Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hormone therapy--recent advances].

K Matsumoto1, S Noguchi

  • 1Dept. of Pathology, Osaka University Medical School.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|October 1, 1987
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Negative regulation of hepatocyte growth factor gene expression in human lung fibroblasts and leukemic cells by transforming growth factor-beta 1 and glucocorticoids.

The Journal of biological chemistry·1992
Same author

Recombinant variants of tissue-type plasminogen activator containing amino acid substitutions in the finger domain.

Thrombosis and haemostasis·1992
Same author

Rapid and marked induction of hepatocyte growth factor during liver regeneration after ischemic or crush injury.

Hepatology (Baltimore, Md.)·1992
Same author

[Clinical manifestation and prognosis of respiratory syncytial virus infection in infants].

Arerugi = [Allergy]·1992
Same author

Sensitive period for the induction of endoreduplication by rotenone in cultured Chinese hamster cells.

Chromosoma·1992
Same author

Ki-67 antibody labeling index in colorectal carcinoma.

Journal of clinical gastroenterology·1992
Same journal

[A Case of Pulmonary Epithelioid Hemangioendothelioma Associated with Multiple Cancers].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Long-Term Survival in Three Cases with Pulmonary Metastases from Colorectal Cancer Given Low-Dose S-1 Under a Regimen Combining a Carbohydrate-Restricted Ketogenic Diet, Metformin, Vitamin D, Eicosapentaenoic Acid, and Other Complementary Therapies].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Preventive Effect of Saline Eye Wash for Eye Symptoms Due to High-Dose and Intermediate-Dose Cytarabine Therapy].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Examination of Factors Affecting the Efficacy of Naldemedine Tosilate Tablets for Opioid-Induced Constipation].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Recent Advances in the Treatment of HER2-Altered Solid Tumors].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[BRAF-Mutant Solid Tumor].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
See all related articles

Hormone therapy can inhibit hormone-stimulated cancers like breast, endometrial, and prostate cancers, but resistance often develops. Future therapies may target growth factors involved in hormone-independent cancer growth.

Area of Science:

  • Oncology
  • Endocrinology
  • Cancer Biology

Context:

  • Hormone therapy is a key treatment for hormone-dependent cancers, including breast, endometrial, and prostate cancers.
  • Traditional therapies involve surgical removal of hormone-producing organs or medicinal suppression of hormone production/action.
  • Recent advances include medicinal therapies like antiestrogens, antiandrogens, and GnRH analogs.

Purpose:

  • To review the efficacy and limitations of current hormone therapies for hormone-dependent cancers.
  • To explore the mechanisms of resistance to hormone therapy and the development of hormone-independent tumors.
  • To discuss potential future directions for endocrine therapy, including targeting growth factors.

Summary:

  • Hormone therapy effectively treats cancers dependent on estrogen or androgen, but its efficacy is limited (30-70%) and resistance often emerges.

Related Experiment Videos

  • While chemoendocrine therapies show increased response rates, they haven't significantly improved overall survival.
  • Emerging research suggests targeting autocrine growth factor signaling may offer a novel therapeutic strategy for hormone-independent cancers.

    • Impact:

    • Highlights the need for novel therapeutic strategies to overcome hormone resistance in cancer treatment.
    • Identifies growth factor signaling as a promising target for future endocrine therapies.
    • Provides a comprehensive overview of hormone therapy's role and future prospects in oncology.